Skip to main content

Talk Bio

Search This Blog

Trump floats countdown to 200% tariffs on generic drugs imported to US

on July 22, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

proposed 200% tariff on imported medicines

200% tariff on generic drugs imported to US

watch out for tariffs on generic drugs

Sources:

"It doesn't make a lot of sense": Trump's 200% tariff plan for ...

Trump says generic drugs to face no US tariffs for 2 years ...

Trump unveils phased generic drug tariffs

Trump Threatens to Impose Tariffs on Generic Drugs

Trump threatens 200% tariffs on generic drugs in 2028, wants manufacturing to move to US | Company Business News

Trump threatens new tariffs on generic drug makers to take effect in two years

Trump plans drug tariffs of up to 250%

Could Trump's Drug Tariff Threaten US Low-Cost Medicine Supply? | The Pulse 7/22/2026

Trump's pharma tariffs: Big hits, bigger loopholes

Trump announces 200% tariff on generic drugs, may impact ...

Trump Announces New Tariffs on Generic Drugs | Big Impact ...

US President Donald Trump says generic drugs imported ...

Trump Threatens 200% Tariff On Indian Pharma! Why India ...

‘Drug companies will have problems’: Trump unveils 200% tariff plan to slash soaring drug prices

Trump plans 200% tariff on imported drugs, raising risk of ...

100% 200 a year later August 2028 August 2029 Generic Drug Makers levy production Transplant Registry Unified Management Program Trump floats U.S.

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer

Rivus Pharmaceuticals announced on February 25, 2026, the appointment of Jorge Bartolome as Chief Executive Officer and Board member, succeeding co-founder Allen Cunningham who transitions to Chief Operating Officer. 1 2 Jorge Bartolome brings over 25 years of experience, including CEO of AreteiaTx, President of Janssen Canada, and senior roles at GSK generating $8 billion in sales. 1 2 Rivus focuses on oral therapies for MASH, obesity, and cardiometabolic diseases, with lead candidate HU6 (oral mitochondrial uncoupler) succeeding in three Phase 2 trials. 1 2 2026 plans include advancing HU6 in the AMPLIFY Phase 2 trial for MASH and initiating first clinical trial for RV-8451, an oral muscle-preserving GLP-1 for obesity. 1 2 Ian F. Smith, Co-Chair of the Board, highlighted Bartolome's expertise in late-stage development and commercialization as ideal for Rivus' growth. 1 2 Sources: 1. https://www.globenewswire.com/news-release/2026/02/25/3244576/0/en/Rivus-Pharmaceu...

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

OKYO Pharma Appoints Flavio Mantelli, MD, PhD as Chief Medical Officer

OKYO Pharma announced on February 10, 2026, the appointment of Flavio Mantelli, MD, PhD, as Chief Medical Officer to lead clinical and regulatory strategy for urcosimod in neuropathic corneal pain (NCP). Dr. Mantelli previously served as CMO at Dompé, where he led the clinical development, FDA approval, and global strategy for Oxervate®, a blockbuster orphan drug with over $1 billion in sales in 2024. Urcosimod has FDA Fast Track designation for NCP, with a planned ~150-subject Phase 2b/3 multiple-dose study expected to start in H1 2026. This appointment follows the recent hiring of CEO Robert Dempsey and strengthens OKYO's ophthalmology leadership team. OKYO Pharma shares rose 10.80% intraday following the announcement. Sources:

Powered by Blogger

X-Data LLC